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Introduction
The composite score JADAS1, 2 27-CRP (J27), 10-CRP
(J10), and cut-off values for inactive (ID), low (LDA),
moderate (MDA) and high disease activity (HDA) were
designed to monitor the level of disease activity in all
JIA subtypes1. The efficacy of canakinumab (CAN), a
selective, human, anti-IL-1b monoclonal antibody, was
previously demonstrated in SJIA in phase III trials using
aACR-JIA response criteria3.
Objectives
To assess the level of disease activity in CAN-treated
SJIA patients, using J10 and J27 in a 12-week pooled
(phase III studies) data set.
Methods
Patients, 2–19 years of age, with active SJIA were
enrolled and received sc CAN 4 mg/kg. This post-hoc
analysis focuses on a 12-week pooled dataset (from
3 phase III studies) in a total of 178 CAN-naïve patients,
assessing the J10 and J27 scores at Days (D) 15, 29, 57,
85, and applies the appropriate cut-off values for ID,
LDA, MDA and HDA.
Results
At baseline, the median [Q1,Q3] J10 for completer
patients (i.e. patients who complete 12 weeks treatment)
was 29.1 [23.1,33.2], and the median change [Q1,Q3]
from baseline at D15 and D85 was -19.4 [-25.7,-13.4]
and -21.2 [-27.7,-16.7], respectively. Results for J27 were
very similar. The disease status at all time points for J10
and J27 are reported in Table 1. Median change from
baseline at each time point was consistent between the
completers and the full analysis dataset for J10 and J27.
Conclusion
In the pooled 12-week dataset, there was a dramatic
reduction in disease activity from baseline to D85, with
much of the reduction taking place by D15 onwards in
both completers and in the full analysis set. An increasing
proportion of CAN patients achieved ID or LDA -
according to J10 and J27 - in the first 12 weeks of treat-
ment, despite corticosteroid tapering, a finding consistent
with that using the previous ID definition from the phase
III trials. These data confirm the early onset of effect as
well as the short-term and sustained efficacy over 12
weeks of canakinumab, and suggest that JADAS may
represent a useful tool to monitor treatment response.
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Table 1 J10 and J27-related disease criteria on all
patients










J10 ID 0.0 18.0 26.8 34.4 33.6
LDA 0.0 14.0 11.5 16.8 24.8
MDA 0.6 19.2 19.7 20.6 16.8
HDA 99.4 48.8 42.0 28.2 24.8
J27 ID 0.0 18.0 26.8 34.4 33.6
LDA 0.0 14.0 11.5 16.8 25.6
MDA 0.6 15.1 16.6 17.6 12.8
HDA 99.4 52.9 45.2 31.3 28.0
*Cut-off values for ID, LDA, MDA and HDA, respectively for J10: ≤1, >1-≤3.8,
>3.8 - ≤10.5, >10.5; and for J27: ≤1, >1 - ≤3.8, >3.8 - ≤8.5, >8.5
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